The Present Status of Monoamine Oxidase Inhibitors
- 1 June 1985
- journal article
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 146 (6), 576-584
- https://doi.org/10.1192/bjp.146.6.576
Abstract
Summary: The present status of monoamine oxidase inhibitors in the treatment of depression is reviewed. With adequate doses they are effective antidepressants, but dosages have in the past been too low. Provided proper dietary precautions are taken, the incidence of fatality from dietary interactions is very small and should not deter doctors from using these drugs, especially in those depressed patients who do not respond to tricyclic-type antidepressants. The present status of combining monoamine oxidase inhibitors with tricyclics is discussed, as are the newer specific inhibitors particularly clorgyline and deprenyl.Keywords
This publication has 66 references indexed in Scilit:
- L-deprenyl plus l-phenylalanine in the treatment of depressionJournal of Neural Transmission, 1984
- IsocarboxazidJournal of Affective Disorders, 1983
- Regulation of recognition and action function of the norepinephrine (NE) receptor-coupled adenylate cyclase system in brain: Implications for the therapy of depressionNeuropharmacology, 1983
- WILL AMITRIPTYLINE PREVENT THE "CHEESE" REACTION OF MONOAMINE-OXIDASE INHIBITORS?The Lancet, 1982
- The Effect of Treatment on the Melancholias (Depressions)The British Journal of Psychiatry, 1982
- Reevaluation of the indoleamine hypothesis of depression. Evidence for a reduction of functional activity of central 5-HT systems by antidepressant drugsJournal of Neural Transmission, 1979
- Acetylator status and inhibition of platelet monoamine oxidase following treatment with pheneizinePsychological Medicine, 1979
- Letter: Interactions with monoamine oxidase inhibitors.BMJ, 1975
- Drug Resistant Depressions: Response to E.C.T.Pharmacopsychiatry, 1974